Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Controlled, Open-label, Phase IIa Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Adjuvant Treatment of Non-small Cell Lung Cancer With Negative Driver Gene Mutations

NCT07444437 is registered in ClinicalTrials.gov with Suzhou BlueHorse Therapeutics Co., Ltd. as lead sponsor.

NCT NCT07444437
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07444437 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Controlled, Open-label, Phase IIa Trial on Autologous Tumor Infiltrating Lymphocyte Injection (LM103 TILs) for the Adjuvant Treatment of Non-small Cell Lung Cancer With Negative Driver Gene Mutations
Lead sponsor
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
February 26, 2026
Completion date
December 31, 2028
Enrollment
45 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer